Nikhil Prasad Fact checked by:Thailand Medical News Team Apr 18, 2026 1 hour, 43 minutes ago
Medical News: Real-World Data Raises Fresh Questions
A new large-scale safety analysis is shedding light on the real-world effects of vutrisiran, a relatively new treatment used for patients suffering from transthyretin-mediated amyloidosis with polyneuropathy. While the drug has been praised for its ability to slow disease progression, researchers are now warning that its safety profile may be more complex than initially believed.
New research reveals potential risks and delayed side effects linked to vutrisiran treatment
The study analyzed adverse drug reaction reports from two major global databases—WHO-VigiAccess and the U.S. FDA’s FAERS system—covering hundreds of patient cases. In total, 721 reports were identified in VigiAccess and 732 in FAERS, offering one of the most comprehensive looks yet at how patients respond to the drug outside controlled clinical trials.
Who Conducted the Research
The research was conducted by scientists from multiple institutions in China, including The Affiliated Taian City Central Hospital of Qingdao University, Qilu Hospital of Shandong University, Sichuan Provincial People’s Hospital at the University of Electronic Science and Technology of China, Shandong University of Traditional Chinese Medicine, and The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital.
Common Side Effects Confirmed
The findings confirmed several already known side effects of vutrisiran. These include reactions at the injection site such as redness, swelling, and pain. Many patients also reported fatigue, muscle pain, and discomfort in the arms and legs.
Another key concern identified was a drop in vitamin A levels. This is particularly important because vitamin A plays a critical role in maintaining vision and immune health. The reduction appears to be linked directly to how the drug works in the body by interfering with transthyretin protein production.
Study Highlights New Risks
Interestingly, the study covered in this
Medical News report also discovered several potential safety signals that had not been widely recognized before. Among these were cases of night blindness, heart rhythm issues requiring pacemakers, and even reports linked to surgical procedures such as heart or kidney transplants.
It is important to understand that these signals do not necessarily mean the drug directly causes these outcomes. In many cases, they may reflect the severity of the underlying disease rather than the medication itself. However, the consistent appearance of these patterns suggests they should not be ignored.
Timing of Side Effects Matters
One of the most striking discoveries was when these adverse reactions tend to occur. The data showed that many side effects appear within the first five months of treatment, but the risk continues to rise over time. In fact, the study found that
most adverse events occur within the first year after starting therapy.
A statistical model indicated that side effects may gradually increase rather than appearing immediately. This delayed pattern means patients and doctors need to stay alert long after treatment begins.
Vision and Vitamin A Link Raises Concern
The connection between reduced vitamin A levels and night blindness stood out as particularly significant. Night blindness can seriously affect a person’s quality of life, especially in low-light conditions. Researchers suggest that patients taking vutrisiran may benefit from careful monitoring of vitamin A levels and possibly supplementation when needed.
Heart and Bone Health Signals
The study also pointed to possible links between vutrisiran and heart rhythm problems. Some patients required pacemakers, which are typically used when the heart beats too slowly or irregularly. However, since heart complications are already common in amyloidosis patients, it remains unclear whether the drug is directly responsible.
Additionally, there were signals suggesting a possible association with bone issues such as fractures. This may again be related to vitamin A imbalance, which plays a role in bone strength and health.
Conclusion
Overall, the findings highlight that while vutrisiran remains an important treatment option, its safety profile requires ongoing monitoring in real-world settings. Patients may experience both expected and unexpected side effects, some of which could emerge months after starting therapy. The study emphasizes the need for regular follow-ups, especially within the first year, along with proactive management of risks such as vitamin A deficiency and potential heart complications. Importantly, many of the more serious signals may reflect the progression of the disease itself rather than direct drug toxicity, but they still warrant careful attention and further investigation.
The study findings were published in the peer reviewed journal: PLOS One.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0347417
For the latest on the safety profile of the drug Vutrisiran, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/articles/med-news
Share
Tweet
Share
